CSL Ltd (ASX: CSL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

CSL Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $135.76 billion
P/E Ratio 36.53
Dividend Yield 1.36%
Shares Outstanding 483.25 million
Earnings per share 5.090
Dividend per share 3.81
Year To Date Return -1.37%
Earnings Yield 2.74%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • CSL Ltd (ASX: CSL)
    Latest News

    Woman relaxing on her phone on her couch, symbolising passive income.
    Dividend Investing

    How much passive income will I get from shares vs. property?

    We compare current rental yields across Australia to some of the best dividend-paying ASX shares.

    Read more »

    Cropped shot of an attractive young female scientist working on her computer in the laboratory.
    Healthcare Shares

    Why are CSL shares falling today?

    CSL shareholders may have mixed feelings today.

    Read more »

    A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
    Share Market News

    5 things to watch on the ASX 200 on Monday

    The Australian share market looks to have run out of steam on Monday.

    Read more »

    Man holding fifty Australian Dollar banknote in his hands, symbolising dividends, symbolising dividends.
    Broker Notes

    3 ASX shares you can confidently invest $500 in right now

    Analysts are saying good things about these high-quality companies.

    Read more »

    Beautiful holiday photo showing two deck chairs close-up with people sitting in them enjoying the bright blue ocean and island view while sipping champagne and enjoying the good life thanks to Pilbara Minerals share price gains in recent times
    How to invest

    1 ASX stock that has created millionaires and will continue to make more

    A big return could be on the cards this year according to UBS. Could more be on the way?

    Read more »

    Woman smiling with her hands behind her back on her couch, symbolising passive income.
    Dividend Investing

    13 ASX 200 shares with ex-dividend dates next week

    Do you own any of the shares scheduled to go 'ex-div' next week?

    Read more »

    A businesswoman on the phone is shocked as she looks at her watch, she's running out of time.
    Share Market News

    Want to grab the CSL dividend? There's not much time left!

    Time is almost up for the dividend.

    Read more »

    Three people in a corporate office pour over a tablet, ready to invest.
    Broker Notes

    Morgans names the best ASX 200 stocks to buy in March

    Morgans expects strong returns from these top ASX 200 shares over the next 12 months.

    Read more »

    Shot of a mature scientists working on a laptop in a lab.
    Healthcare Shares

    Is this a new threat for CSL shares?

    There's a new wonder drug on the scene. Should shareholders be concerned?

    Read more »

    A smiling young surf life saver at the beach shouts out on a megaphone.
    Best Shares

    Top ASX shares to buy in March 2024

    Shout out for the first day of autumn! Are you letting 2024's ASX gains flow your way?

    Read more »

    Young businesswoman sitting in kitchen and working on laptop.
    Broker Notes

    3 no-brainer ASX shares to buy under $30

    Analysts think these shares are top buys for investors right now.

    Read more »

    Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
    Healthcare Shares

    Has the CSL share price got further to fall?

    ASX experts weigh in on what's next for CSL.

    Read more »

    Frequently Asked Questions

    CSL originally floated in 1994 at $2.30 per share. However, taking into account share buybacks, the adjusted entry price is equivalent to around 76 cents. 

    CSL has paid twice yearly dividends every year since late 1997, a little over three years after the company’s initial listing on the ASX. Up until early 2005, CSL’s dividends were all fully franked. Since then, franking credits have been intermittent.

    In the period since April 2012, CSL has paid unfranked dividend payments to shareholders annually in April and October, with the exception of a 10% franked final dividend payment made in September 2021.

    CSL has a dividend reinvestment plan, however, it has not been active since 2004. Instead, CSL periodically executes share buybacks as a way of delivering additional returns for shareholders.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    11 Mar 2024 $1.7989 0.00% Interim 03 Apr 2024
    11 Sep 2023 $2.0078 6.42% Final 04 Oct 2023
    09 Mar 2023 $1.6215 0.00% Interim 05 Apr 2023
    06 Sep 2022 $1.7583 10.00% Final 05 Oct 2022
    07 Mar 2022 $1.4229 0.00% Interim 06 Apr 2022
    02 Sep 2021 $1.5897 10.00% Final 30 Sep 2021
    04 Mar 2021 $1.3491 0.00% Interim 01 Apr 2021
    10 Sep 2020 $1.4696 0.00% Final 09 Oct 2020
    11 Mar 2020 $1.4713 0.00% Interim 09 Apr 2020
    10 Sep 2019 $1.4545 0.00% Final 11 Oct 2019
    13 Mar 2019 $1.2032 0.00% Interim 12 Apr 2019
    11 Sep 2018 $1.2782 0.00% Final 12 Oct 2018
    14 Mar 2018 $1.0050 0.00% Interim 13 Apr 2018
    12 Sep 2017 $0.0000 0.00% Final 13 Oct 2017
    15 Mar 2017 $0.8378 0.00% Interim 13 Apr 2017
    13 Sep 2016 $0.8867 0.00% Final 07 Oct 2016
    23 Mar 2016 $0.8147 0.00% Interim 15 Apr 2016
    07 Sep 2015 $0.8999 0.00% Final 02 Oct 2015
    16 Mar 2015 $0.7439 0.00% Interim 10 Apr 2015
    08 Sep 2014 $0.6485 0.00% Final 03 Oct 2014
    05 Mar 2014 $0.5888 0.00% Interim 04 Apr 2014
    09 Sep 2013 $0.5698 0.00% Final 04 Oct 2013
    05 Mar 2013 $0.3406 0.00% Interim 05 Apr 2013
    17 Sep 2012 $0.3290 0.00% Final 12 Oct 2012
    14 Mar 2012 $0.2520 0.00% Interim 13 Apr 2012
    19 Sep 2011 $0.3210 6.23% Final 14 Oct 2011
    08 Mar 2011 $0.2450 0.00% Interim 08 Apr 2011
    13 Sep 2010 $0.3308 15.96% Final 08 Oct 2010
    09 Mar 2010 $0.2450 0.00% Interim 09 Apr 2010
    14 Sep 2009 $0.2800 0.00% Final 09 Oct 2009
    17 Sep 2007 $0.4675 58.82% Final 12 Oct 2007
    14 Mar 2006 $0.1960 0.00% Interim 13 Apr 2006
    30 Aug 2005 $0.0753 23.64% Special 10 Oct 2005
    30 Aug 2005 $0.3000 100.00% Final 10 Oct 2005
    29 Mar 2004 $0.1200 100.00% Interim 13 Apr 2004

    CSL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About CSL Ltd

    CSL Limited (ASX: CSL) is an Australian-based global biotechnology company that develops and delivers biotherapies and vaccines to protect public health and help people with life-threatening medical conditions live full lives.

    CSL has been in operation for more than a century and was listed on the ASX in 1994. Today, the blue-chip healthcare company is one of the largest on the ASX.

    CSL’s operational businesses include CSL Behring and Seqirus. Its Plasma business operates one of the largest plasma collection networks in the world. CSL is recognised for its global leadership in three main areas: rare and serious diseases, vaccine development, and iron deficiency and nephrology (kidney research).

    The company operates predominantly in Australia, the United States, Germany, the United Kingdom, and Switzerland.

     

    CSL Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    24 May 2024 $280.92 $-1.08 -0.38% 564,716 $279.09 $281.93 $279.04
    23 May 2024 $282.00 $3.91 1.41% 769,925 $278.43 $283.03 $278.02
    22 May 2024 $278.09 $0.46 0.17% 597,796 $278.00 $280.10 $277.20
    21 May 2024 $277.63 $-0.27 -0.10% 783,076 $277.94 $279.11 $276.35
    20 May 2024 $277.90 $-2.10 -0.75% 421,764 $280.53 $281.98 $277.90
    17 May 2024 $280.00 $-6.95 -2.42% 1,404,153 $285.50 $285.54 $279.66
    16 May 2024 $286.95 $3.90 1.38% 968,347 $286.49 $287.25 $284.10
    15 May 2024 $283.05 $3.47 1.24% 594,466 $281.90 $284.50 $281.02
    14 May 2024 $279.58 $-0.34 -0.12% 562,022 $279.97 $282.07 $278.94
    13 May 2024 $279.92 $0.74 0.27% 436,936 $278.87 $280.30 $278.20
    10 May 2024 $279.18 $2.13 0.77% 485,383 $276.86 $280.43 $276.02
    09 May 2024 $277.05 $-2.85 -1.02% 621,078 $276.54 $277.10 $275.10
    08 May 2024 $279.90 $0.34 0.12% 494,169 $279.74 $281.78 $278.67
    07 May 2024 $279.56 $4.06 1.47% 730,830 $277.50 $280.00 $276.24
    06 May 2024 $275.50 $-0.30 -0.11% 501,267 $276.76 $277.00 $275.36
    03 May 2024 $275.80 $0.41 0.15% 472,252 $276.00 $277.50 $274.44
    02 May 2024 $275.39 $0.90 0.33% 545,861 $274.68 $276.45 $273.87
    01 May 2024 $274.49 $-2.27 -0.82% 397,687 $274.92 $276.28 $274.08
    30 Apr 2024 $276.76 $1.76 0.64% 558,435 $274.45 $276.97 $274.30
    29 Apr 2024 $275.00 $1.70 0.62% 448,029 $274.75 $275.49 $272.56

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    21 Feb 2024 Samantha (Sam) Lewis Issued 114 $32,190
    Director remuneration. VWAP
    16 Feb 2024 Marie McDonald Buy 145 $41,180
    Conversion of securities.
    16 Feb 2024 Marie McDonald Exercise 145 $41,180
    Conversion of securities. 145 Right
    16 Feb 2024 Megan Clark Buy 145 $41,180
    Conversion of securities.
    16 Feb 2024 Megan Clark Exercise 145 $41,180
    Conversion of securities. 145 Rights
    16 Feb 2024 Carolyn Hewson Buy 193 $54,812
    Conversion of securities.
    16 Feb 2024 Carolyn Hewson Exercise 193 $54,812
    Conversion of securities. 193 Rights
    16 Feb 2024 Alison Watkins Exercise 169 $47,996
    Conversion of securities. 169 Rights
    16 Feb 2024 Alison Watkins Buy 169 $47,996
    Conversion of securities.
    16 Feb 2024 Brian McNamee Buy 343 $97,412
    Conversion of securities.
    16 Feb 2024 Brian McNamee Exercise 343 $97,412
    Conversion of securities. 343 Rights
    16 Feb 2024 Robert Cuthbertson Exercise 145 $41,180
    Conversion of securities. 145 Rights
    16 Feb 2024 Robert Cuthbertson Buy 145 $41,180
    Conversion of securities.
    16 Feb 2024 Duncan Maskell Exercise 339 $96,276
    Conversion of securities. 338 Rights
    16 Feb 2024 Duncan Maskell Buy 339 $96,276
    Conversion of securities.
    20 Oct 2023 Megan Clark Buy 210 $49,939
    On-market trade.
    12 Oct 2023 Paul McKenzie Issued 44,095 $10,505,192
    Issue of securities. 84,474 Performance Share Units
    01 Sep 2023 Paul McKenzie Expiry 5,384 $1,448,780
    As advised by the company. 40,379 Rights, lapsed
    01 Sep 2023 Paul McKenzie Sell 1,361 $365,563
    On-market trade.
    01 Sep 2023 Paul McKenzie Exercise 3,120 $839,560
    Conversion of securities. 45,763 Rights
    01 Sep 2023 Paul McKenzie Buy 3,120 $839,560
    Conversion of securities.
    01 Sep 2023 Robert Cuthbertson Expiry 1,161 $312,413
    As advised by the company. 290 Right, Lapsed
    25 Aug 2023 Robert Cuthbertson Sell 20,000 $5,310,979
    On-market trade. AVERAGE PRICE
    24 Aug 2023 Brian McNamee Sell 21,000 $5,585,222
    On-market trade. average price
    23 Aug 2023 Brian McNamee Issued 686 $184,519
    Issue of securities. VWAP, 686 Rights
    23 Aug 2023 Robert Cuthbertson Issued 290 $78,003
    Issue of securities. VWAP, 1,451 Rights, PSU
    23 Aug 2023 Duncan Maskell Issued 677 $182,098
    Issue of securities. 677 Rights, VWAP
    23 Aug 2023 Bruce Brook Issued 193 $51,912
    Issue of securities. 193 Rights, vwap
    23 Aug 2023 Carolyn Hewson Issued 386 $101,595
    Conversion of securities. 386 Rights
    23 Aug 2023 Alison Watkins Issued 338 $90,914
    Issue of securities. 338 Rights, VWAP
    23 Aug 2023 Marie McDonald Issued 290 $79,003
    Issue of securities. 290 Rights, VWAP
    23 Aug 2023 Megan Clark Issued 290 $78,003
    Issue of securities. VWAP
    21 Aug 2023 Megan Clark Exercise 85 $22,683
    Conversion of securities.
    21 Aug 2023 Megan Clark Buy 85 $22,683
    Conversion of securities.
    21 Aug 2023 Carolyn Hewson Exercise 214 $57,108
    Conversion of securities.
    21 Aug 2023 Carolyn Hewson Buy 214 $57,108
    Conversion of securities.
    21 Aug 2023 Alison Watkins Buy 150 $40,029
    Conversion of securities.
    21 Aug 2023 Alison Watkins Exercise 150 $40,029
    Conversion of securities.
    21 Aug 2023 Robert Cuthbertson Buy 128 $34,158
    Conversion of securities.
    21 Aug 2023 Robert Cuthbertson Exercise 128 $34,158
    Conversion of securities. 1,161 psU
    21 Aug 2023 Brian McNamee Buy 304 $81,125
    Conversion of securities.
    21 Aug 2023 Brian McNamee Exercise 304 $81,125
    Conversion of securities.
    21 Aug 2023 Duncan Maskell Exercise 300 $80,058
    Conversion of securities.
    21 Aug 2023 Duncan Maskell Buy 300 $80,058
    Conversion of securities.
    21 Aug 2023 Marie McDonald Exercise 128 $34,158
    Conversion of securities.
    21 Aug 2023 Marie McDonald Buy 128 $34,158
    Conversion of securities.
    21 Aug 2023 Bruce Brook Buy 257 $68,583
    Conversion of securities.
    21 Aug 2023 Bruce Brook Exercise 257 $68,583
    Conversion of securities.
    18 Aug 2023 Megan Clark Buy 220 $59,859
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Carolyn Judith Hewson Non-Executive Director Dec 2019
    Ms Hewson is a former investment banker with over 35 years experience in the finance sector. She was previously an executive director of Schroders Australia Limited and has extensive financial markets, risk management and investment management expertise. She has long-term Non-Executive experience in a number of sectors bringing experience and insight on strategy, capital management and portfolio optimisation through cycles, financial and non-financial risk, social value, organisational culture and the changing external environment. In 2009, Ms Hewson was made an Officer of the Order of Australia for her services to the broader community and to business. She is a Director of Reserve Bank of Australia (since April 2021), Director of Infrastructure SA (since January 2019), Former Member of Federal Government Growth Centres Advisory Committee (from January 2015 to May 2021), Former Director of BHP Group Limited and BHP Group Plc (from March 2010 to November 2019) and Former Trustee Westpac Foundation (from May 2015 to May 2019). She is a Chair of the Corporate Governance Committee, Member of the Risk Management Committee and Member of the Human Resources Committee.
    Ms Alison Mary Watkins Non-Executive Director Aug 2021
    -
    Dr Brian Anthony McNamee Non-Executive DirectorNon-Executive Chairman Jan 1990
    Dr McNamee has executive experience in the biopharmaceutical industry. Dr McNamee has served as a senior advisor to private equity group Kohlberg Kravis Roberts. He has also pursued a number of private equity and interests in small cap healthcare companies, and in 2014 served on the panel of the Australian Government's Financial System Inquiry. He is Chair of Geoff Ogilvy Foundation (since May 2021) and Former Chair of GenesisCare Limited (from July 2019 to June 2022). He is a Member of the Innovation and Development Committee, Corporate Governance Committee and Securities and Market Disclosure Committee.
    Dr Robert Andrew Cuthbertson Non-Executive Director Oct 2018
    Dr Cuthbertson has over 35 years experience in medical research and biotech development with biopharmaceutical companies and medical organisations. Prior to CSL, he was a senior scientist at Genentech Inc. Professor Cuthbertson spent five years doing molecular biology research as a staff member at the Howard Florey Institute in Melbourne, Australia and the National Institutes of Health in Maryland, US. In 2016, he was made an Officer of the Order of Australia and appointed Enterprise Professor at the University of Melbourne. He is a Member of the Council of the University of Melbourne (since January 2020), Director of the Grattan Institute (since January 2019) and Director of the Centre of Eye Research Australia (since March 2017). He is a Chair of the Innovation and Development Committee and Member of the Corporate Governance Committee.
    Professor Duncan John Maskell Non-Executive Director Aug 2021
    Professor Maskell has international experience in science and commerce, with a focus in research, academia and entrepreneurship. Prior to this he was senior pro-vice-chancellor at the University of Cambridge in the UK and has also held roles at the University of Oxford, Imperial College London and Wellcome Biotech. Professor Maskell has experience across the private sector, reflecting his passion for the commercialisation of research initiatives. He has co-founded several biotech companies, including Arrow Therapeutics, which was sold to biopharmaceutical company AstraZeneca, and Discuva, which was sold to Summit Therapeutics. He has also served as a Non-Executive Director of Genus Plc, a FTSE 250 company. He is a a Director of the Grattan Institute (since November 2018), Vice-Chancellor of the University of Melbourne (since October 2018), Director of Melbourne Business School (since October 2018), Director of the Group of Eight Limited (since October 2018) and Director of Universities Australia Limited (since October 2018). He is a Member of the Innovation and Development Committee.
    Ms Marie Elizabeth McDonald Non-Executive Director Aug 2013
    -
    Ms Samantha (Sam) Louise Lewis Non-Executive Director Jan 2024
    --
    Dr Megan Elizabeth Clark Non-Executive Director Feb 2016
    Dr Clark has executive and Non-Executive experience across a range of sectors, including scientific research, health, investment banking and financial services, education and mining. Through her roles, Dr Clark brings a global experience, with a focus on risk and proven health, safety and environment and technology performance. Dr Clark was chief executive of the Commonwealth Scientific and Industrial Research Organisation (CSIRO) from 2009 until November 2014. Prior to joining CSIRO, she was a director at NM Rothschild and Sons (Australia) and held senior positions at BHP, including vice president (Technology) and vice president (Health, Safety and Environment). She is a Deputy Chancellor of Monash University (since January 2021), Chair of the Australian Space Agency Advisory Board (since January 2021), Member of the Global Advisory Council of the Bank of America Corporation (since December 2019), Director of Rio Tinto Limited and Rio Tinto Plc (since November 2014), Member of the Australian Advisory Board of the Bank of America (since July 2010), Former Head of the Australian Space Agency (from June 2018 to December 2020) and Care Australia Limited (from May 2015 to June 2020). She is a Chair of the Human Resources Committee, Member of the Corporate Governance Committee and Innovation and Development Committee.
    Dr Paul McKenzie Chief Operating OfficerExecutive DirectorChief Executive OfficerManaging Director Dec 2022
    Dr McKenzie has than 30 years of leadership experience in the global biotechnology industry, including managing complex organisations through compelling growth and transformation. Since joining CSL as COO in 2019, Prior to joining CSL, Dr McKenzie was Executive Vice President of Pharmaceutical Operations & Technology at Biogen. He also served in a range of progressively senior level roles in R&D and manufacturing at Johnson & Johnson, Bristol-Myers Squibb and Merck.
    Ms Fiona Mead Company SecretaryHead of Group Governance Jun 2018
    -
    Fiona Mead Company SecretaryHead of Group Governance
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 158,208,692 32.80%
    J P Morgan Nominees Australia Pty Limited 81,652,973 16.93%
    Citicorp Nominees Pty Limited 45,017,523 9.33%
    National Nominees Limited 15,121,161 3.13%
    BNP Paribas Noms Pty Ltd <Drp> 12,608,974 2.61%
    Bnp Paribas Nominees Pty Ltd <Agency Lending Drp A/C> 4,832,402 1.00%
    Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 4,734,581 0.98%
    Hsbc Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> 3,278,217 0.68%
    Netwealth Investments Limited <Wrap Services A/C> 2,568,812 0.53%
    Australian Foundation Investment Company Limited 2,239,500 0.46%
    Bnp Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> 2,163,373 0.45%
    Custodial Services Limited <Beneficiaries Holding A/C> 1,665,903 0.35%
    Solium Nominees (Australia) Pty Ltd <Allocated A/C> 1,574,635 0.33%
    Argo Investments Limited 1,311,509 0.27%
    Bnp Paribas Noms (Nz) Ltd <Drp> 898,418 0.19%
    Mutual Trust Pty Ltd 891,059 0.18%
    D W S Nominees Pty Ltd 793,208 0.16%
    HSBC Custody Nominees (Australia) Limited A/C 2 750,247 0.16%
    BNP Paribas Nominees Pty Ltd <Agency Lending Collateral> 726,200 0.15%
    Solium Nominees (Australia) Pty Ltd <Vsa A/C> 676,661 0.14%

    Profile

    since

    Note